Provided by Tiger Trade Technology Pte. Ltd.

Credit Suisse Holdings

2,469.81
+26.231.07%
Number of Gainers:54
Number of Losers:41
Number of Flat:2
PE:- -
High:2,480.54
Open:2,443.77
Low:2,443.77
Close:2,443.58
Volume:1.44B
Turnover:296.38B
Market Cap:51.71T
Float Cap:48.39T

Loading ...

Monolithic Power Systems Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 26

Digital Realty Trust Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 26

Adobe Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 26

Global Markets-Battered Bonds Draw Support from Falling Oil Prices

Reuters
·
Sep 26

Coca-Cola Taps Monster Exec as President of North American Unit

Dow Jones
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

IWM ETF Climbs 0.1%

Dow Jones
·
Sep 26

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

VOO ETF Gains 0.5%

Dow Jones
·
Sep 26

ServiceNow Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Salesforce Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 26

Intel Corp. Stock Sheds 3.4%, Underperforms Peers

Dow Jones
·
Sep 26

Microsoft Corp. Stock Advances 3.7%, Outperforms Peers

Dow Jones
·
Sep 26

Texas Instruments Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

PayPal Holdings Inc. Stock Rises 4.6%, Outperforms Peers

Dow Jones
·
Sep 26

OpenAI Works to Understand Full Scope of Agent Activity as User Data Leak Emerges

Reuters
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26